Pro Medicus (ASX:PME) share price sinks despite new deal

The Pro Medicus (ASX: PME) share price is a poor performer so far today, despite the company announcing a positive update. We take a look.

| More on:
falling healthcare asx share price Mesoblast capital raising

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Limited (ASX: PME) share price is a poor performer so far on Thursday despite the company providing a positive update. In early morning trade, the health imaging company's shares are fetching $40.05, down 1.26%.

What was announced?

Investors have been selling Pro Medicus shares regardless of the company's announced contract win.

According to its release, Pro Medicus' wholly-owned United Stated subsidiary, Visage Imaging Inc., has signed a deal with The University of Vermont Health Network Inc (UVM).

Under the agreement, Pro Medicus will deploy its Visage 7 Enterprise Imaging Platform across 6 hospitals operated by UVM. It is expected that, once the system is fully functional, a unified diagnostic imaging platform will run across the network. This replaces the existing multiple legacy PACS platforms that are currently being used.

The contract is valid for a period of 8 years and is estimated to generate $14 million in revenue for Pro Medicus.

Rollout of the system is scheduled to commence immediately, with go-live dates targeted for the second half of 2021. The Visage 7 platform will be deployed in the public cloud.

The company noted that the latest deal further expands its United States academic institution footprint. Pro Medicus believes that its transactional licensing model could also lead to further potential sales in the future.

Pro Medicus CEO Dr Sam Hupert commented:

We continue to build momentum in the market with this, our seventh contract win in a row, adding to other recent major announcements.

UVM Health Network is the fourth of these to opt for a cloud-based solution, a trend we see increasing rapidly amongst healthcare systems in North America.

Our pipeline continues to grow. Visage 7 with its proven cloud-native capability provides us with a significant strategic advantage that enables us to address these opportunities across a growing segment of the market both in North America and other regions.

Pro Medicus share price snapshot

Over the last 12 months, the Pro Medicus share price has stormed around 55% higher, with year to date performance delivering gains of around 17%. The company's shares reached an all-time high of $48.69 last month.

Based on valuation grounds, Pro Medicus commands a market capitalisation of around $4.2 billion, with approximately 104 million shares outstanding.

Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two doctors smile as they sit together at a desk looking at a patient's x-ray.
Healthcare Shares

Why Macquarie rates this ASX All Ords medical imaging stock a buy

The broker maintains its outperform rating on the stock.

Read more »

A man in a hospital bed on a drip gives a thumbs up sign.
Healthcare Shares

Macquarie predicts 86% upside for this ASX 200 healthcare stock

Shares could almost double over the next 12 months, according to the broker.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

Ozempic maker Novo Nordisk plunges 22%. What could this mean for Resmed shares?

Novo Nordisk just lost $100 billion in market value.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 11% today

Let's see why investors are bidding this stock higher on Wednesday.

Read more »

stockmarket graphic in background with man looking at stockmarket on phone
Healthcare Shares

CSL shares are a buy – UBS

This expert is optimistic on what the business can achieve despite headwinds.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »